ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Pioglitazone

Also written as “pioglitazone”, “Pioglitazone 30 mg” and “Pioglitazone and azilsartan”.

Its studies are mostly in Diabetes Mellitus, Type 2 · Diabetes Mellitus · Alzheimer Disease · Fatty Liver · Peripheral Arterial Disease, led by 10 companies.

Drug pagePioglitazone: every studyMany companies study it; this page follows only the 52 they lead. All 336 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Jun 27, 200752 company-led studies, 2 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Takeda330 open or runningphase 4since Jun 27, 2007Sep 9, 2005none ahead
Boryung Pharmaceuticalits history only42 open or runningphase 3since May 9, 2021May 9, 2021none ahead
Merckits history only40 open or runningphase 3since Jul 22, 2008Aug 2, 2007none ahead
GlaxoSmithKlineits history only30 open or runningphase 4since Apr 2, 2009Dec 22, 2005none ahead
Hoffmann-La Rocheits history only20 open or runningphase 4since Oct 16, 2007Oct 16, 2007none ahead
Viatrisits history only20 open or runningphase 1since Mar 30, 2008Mar 30, 2008none ahead
Dr. Muhammad Abdulghaniits history only10 open or runningno phasesince Aug 16, 2016Aug 16, 2016none ahead
Getz Pharmaits history only10 open or runningphase 4since Jul 19, 2021Jul 19, 2021none ahead
Medtronicits history only10 open or runningearly phase 1since Jul 21, 2008Jul 21, 2008none ahead
Strekinits history only10 open or runningphase 3since Nov 1, 2017Nov 1, 2017none ahead

Also a collaborator on its studies: Parexel, Zinfandel Pharmaceuticals, Eli Lilly and Takeda Pharmaceuticals North America.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Takeda only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 13 studies since Sep 9, 2005.

  1. Jul 24, 2008Phase 2 study in Diabetes MellitusNCT00722917 · 323 enrolled · United States
  2. Jul 30, 2008Phase 3 study in Diabetes MellitusNCT00727857 · 600 enrolled · United States, Chile, Mexico and more
  3. Sep 17, 2008Phase 4 study in Diabetes MellitusNCT00754403 · 312 enrolled
  4. Sep 26, 2008Phase 2 study in Diabetes MellitusNCT00762736 · 704 enrolled · United States, Argentina, Chile and more
  5. Oct 8, 20083 phase 3 studies in Diabetes MellitusNCT00772174, NCT00770952, NCT00770653
  6. Oct 8, 20082 phase 4 studies in Diabetes MellitusNCT00770835, NCT00770445
  7. Oct 9, 20084 phase 2 studiesNCT00771004, NCT00770640, NCT00770575 and 1 more
  8. May 13, 2010Phase 3 study in Diabetes Mellitus, Type 2NCT01124656 · 26 enrolled
  9. Feb 1, 2011Phase 3 study in Diabetes Mellitus, Type 2NCT01289119 · 506 enrolled · China, Hong Kong, Taiwan
  10. Oct 18, 2011Phase 1 study in HealthyNCT01456117 · 61 enrolled · United States
  11. Aug 31, 2012Phase 4 study in Diabetes MellitusNCT01686711 · 207 enrolled · Japan
  12. Aug 26, 2013Phase 3 study in Mild Cognitive Impairment Due to Alzheimer's DiseaseNCT01931566 · 3,494 enrolled · United States, Australia, Germany and more
  13. Oct 24, 2013Phase 4 study in Diabetes Mellitus, Type 2NCT01972724 · 114 enrolled · Korea, Republic of
  14. Nov 4, 2014Phase 3 study in Mild Cognitive Impairment Due to Alzheimer's DiseaseNCT02284906 · 40 enrolled · United States, Australia, Switzerland and more

TargetBeta

PPARG →read by rule
“Peroxisome proliferator-activated receptor gamma agonist”ChEMBL 37, by rule

Other programs on PPARG

ProgramCompanyFurthest phaseStudies
saroglitazarruleZydus Lifesciencesphase 419
chiglitazarruleChipscreen Biosciencesphase 39
lanifibranorinventiva-pharmaphase 36
T3D-959rulet3d-therapeutics-incphase 33

Studies

All 33 Takeda leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT02284906Mild Cognitive Impairment Due to Alzheimer's Disease · United States, Australia, Switzerland and more3TerminatedJan 31, 201840
NCT01972724Diabetes Mellitus, Type 2 · Korea, Republic of4CompletedOct 17, 2016114
NCT01931566Mild Cognitive Impairment Due to Alzheimer's Disease · United States, Australia, Germany and more3TerminatedJul 24, 20183,494
NCT01686711Diabetes Mellitus · Japan4CompletedDec 2013207
NCT01456117Healthy · United States1CompletedJul 201261
NCT01289119Diabetes Mellitus, Type 2 · China, Hong Kong, Taiwan3CompletedDec 2011506
NCT01124656Diabetes Mellitus, Type 23TerminatedMay 200726
NCT00771004Coronary Artery Disease · Germany2CompletedFeb 200963
NCT00770952Diabetes Mellitus · Germany3CompletedDec 200891
NCT00770653Diabetes Mellitus · Germany3CompletedMay 2009305
NCT00770640Diabetes Mellitus · Germany2CompletedJun 201040
NCT00770575Cardiovascular Diseases2CompletedOct 2006148
NCT00770497Inflammation · Germany2CompletedMay 2008172
NCT00770445Diabetes Mellitus · Germany4CompletedJul 2010121
NCT00772174Diabetes Mellitus3CompletedFeb 2008418
NCT00770835Diabetes Mellitus · Italy4CompletedMay 201139
NCT00762736Diabetes Mellitus · United States, Argentina, Chile and more2CompletedOct 2005704
NCT00754403Diabetes Mellitus4CompletedOct 2006312
NCT00727857Diabetes Mellitus · United States, Chile, Mexico and more3CompletedAug 2008600
NCT00722917Diabetes Mellitus · United States2TerminatedApr 2009323
NCT00708175Glucose Metabolism Disorders · United States4CompletedJan 2011156
NCT00676260Diabetes Mellitus · United Kingdom2CompletedAug 200429
NCT00672919Diabetes Mellitus · United States, Puerto Rico4CompletedAug 2004305
NCT00521820Diabetes Mellitus3TerminatedOct 2003518
NCT00521742Diabetes Mellitus3CompletedJan 2003300
NCT00494312Diabetes Mellitus4CompletedJun 20052,120
NCT00395512Diabetes Mellitus · United States, Argentina, Australia and more3CompletedFeb 2008655
NCT00376181Diabetes Mellitus, Type 2 · United States, Argentina, Chile and more3TerminatedMay 200796
NCT00331487Diabetes Mellitus · United States3CompletedMar 2004719
NCT00328627Diabetes Mellitus, Type 2 · United States, Australia, Brazil and more3CompletedMar 20081,554
NCT00225277Diabetes Mellitus · United States, Argentina, Canada and more3CompletedOct 2007547
NCT00225264Diabetes Mellitus · United States3CompletedMay 2006458
NCT00174993Diabetes Mellitus · Austria, Belgium, Czech Republic and more3CompletedJan 20054,373

How it is read

Names in the registry

  • “Pioglitazone”, 33 entries
  • “pioglitazone”, 5 entries
  • “Pioglitazone 30 mg”, 4 entries
  • “Pioglitazone and azilsartan”, 4 entries
  • “TAK-379”, 3 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.